NYSE:MDT
113.85
1.38
(1.23%)
Medtronic Inc
MDT-N
Analysis and Opinions about MDT-N
Signal
Opinion
Expert
BUY
BUY
A large medical tech company, one of the largest in that field. It is a nice industry that he likes. They deliver consistent earnings growth. It is more of an oligopoly market. It could be a core holding in a portfolio to get medical technology exposure. He holds BSX-N, however.
BUY WEAKNESS
BUY WEAKNESS
November 20, 2020
Sales could be light, because people may be light, because it makes medical devices and people are postponing operations due to Covid. If MDT gets hit, buy it, because a Covid vaccine is coming. It reports Tuesday.
Show full opinionHide full opinion
Sales could be light, because people may be light, because it makes medical devices and people are postponing operations due to Covid. If MDT gets hit, buy it, because a Covid vaccine is coming. It reports Tuesday.
BUY
BUY
October 14, 2020
A premier medical device-maker. Their most recent report beat the street. These medical stocks sold off during the lockdown over fears that surgeries would halt indefinitely, but those fears and sell-offs were overdone.
Show full opinionHide full opinionA premier medical device-maker. Their most recent report beat the street. These medical stocks sold off during the lockdown over fears that surgeries would halt indefinitely, but those fears and sell-offs were overdone.
BUY
BUY
August 18, 2020
Allan Tong’s Discover Picks The Medtronic Stock is one of the largest medical device companies on the globe. It pays a decent dividend of 2.3%, which has grown in the last 28 straight years. MED trades at a 22x PE and has a price target of $110.17, $8 higher than Monday’s trade. MED beat three of its last four quarters, missing its last reported EPS of 68 cents by 10 cents. It boasts a profit margin of 16.56%. Read Cybersecurity Stocks, Clean Energy Stocks and Medical Device Stocks: Little-Known Picks for our full analysis.
Show full opinionHide full opinionAllan Tong’s Discover Picks The Medtronic Stock is one of the largest medical device companies on the globe. It pays a decent dividend of 2.3%, which has grown in the last 28 straight years. MED trades at a 22x PE and has a price target of $110.17, $8 higher than Monday’s trade. MED beat three of its last four quarters, missing its last reported EPS of 68 cents by 10 cents. It boasts a profit margin of 16.56%. Read Cybersecurity Stocks, Clean Energy Stocks and Medical Device Stocks: Little-Known Picks for our full analysis.
TOP PICK
TOP PICK
August 13, 2020
One of the largest device companies in the world. There's a lot of pent-up demand coming for surgeries. It was $120, and now it's around $100. Should see $120 again. Yield is 2.29%. (Analysts’ price target is $110.50)
Show full opinionHide full opinionOne of the largest device companies in the world. There's a lot of pent-up demand coming for surgeries. It was $120, and now it's around $100. Should see $120 again. Yield is 2.29%. (Analysts’ price target is $110.50)
BUY
BUY
August 11, 2020
Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.
Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.
HOLD
HOLD
April 20, 2020
It has grown its dividend 28 consecutive years. Not all of its businesses will be firing. It will not get the same lift because it is not 100% exposed to COVID-19. After COVID the whole diagnostic space will be an interesting one. The dividend is probably relatively safe.
Show full opinionHide full opinionIt has grown its dividend 28 consecutive years. Not all of its businesses will be firing. It will not get the same lift because it is not 100% exposed to COVID-19. After COVID the whole diagnostic space will be an interesting one. The dividend is probably relatively safe.
PAST TOP PICK
PAST TOP PICK
February 18, 2020
(A Top Pick Oct 02/19, Up 7%) They reported today and miss expectations. It's a big global company. There's global demand for their medical devices; in Asia, for instance, there's rising heart disease. So, Medtronic can fulfill this demand.
Show full opinionHide full opinion(A Top Pick Oct 02/19, Up 7%) They reported today and miss expectations. It's a big global company. There's global demand for their medical devices; in Asia, for instance, there's rising heart disease. So, Medtronic can fulfill this demand.
BUY
BUY
January 17, 2020
A large cap diversified company. Their recent acquisition to get into the robotic spine is positive. It has everything for tools and devices, including pacemakers. The chart looks great. This would be the one to own in the space.
Show full opinionHide full opinionA large cap diversified company. Their recent acquisition to get into the robotic spine is positive. It has everything for tools and devices, including pacemakers. The chart looks great. This would be the one to own in the space.
BUY
BUY
October 17, 2019
Good company. Biggest product is pacemakers. Trades at 19x earnings. Good stock price stability. Trades attractively against peers. Given the multiple, and predictability of earnings, you should look at a 10% return or greater over time.
Show full opinionHide full opinionGood company. Biggest product is pacemakers. Trades at 19x earnings. Good stock price stability. Trades attractively against peers. Given the multiple, and predictability of earnings, you should look at a 10% return or greater over time.
TOP PICK
TOP PICK
October 2, 2019
They built the first pacemaker and have gone on to make several similar devices. They have gone global. Places like India need these devices for heart disease, for example. The CEO is from Bangladesh and understands this vast market. They are moving from selling the device to improving people's health. If they succeed, they will be hugely profitable. (Analysts’ price target is $116.38)
Show full opinionHide full opinionThey built the first pacemaker and have gone on to make several similar devices. They have gone global. Places like India need these devices for heart disease, for example. The CEO is from Bangladesh and understands this vast market. They are moving from selling the device to improving people's health. If they succeed, they will be hugely profitable. (Analysts’ price target is $116.38)
BUY
BUY
September 6, 2019
The stock couldn’t look any better. An absolute buy and hold. It took a long time to break through $100 but they’ve done it. Would be a buyer here.
Show full opinionHide full opinionThe stock couldn’t look any better. An absolute buy and hold. It took a long time to break through $100 but they’ve done it. Would be a buyer here.
HOLD
HOLD
May 3, 2019
Don't sell it just to go into a Merck. Add to your diversity instead by buying a basket. Likes Medtronic. Diversified. Into robotic surgery. 8% EPS growth. Relatively inexpensive. Very large, so you don't get the same growth as smaller companies.
Show full opinionHide full opinionDon't sell it just to go into a Merck. Add to your diversity instead by buying a basket. Likes Medtronic. Diversified. Into robotic surgery. 8% EPS growth. Relatively inexpensive. Very large, so you don't get the same growth as smaller companies.
BUY
BUY
December 3, 2018
Likes it very much. Thought bought Covidien, a medical device maker, a few years back. They're executing very well, such as their diabetes franchise which boosted their guidance recently to 5.5% growth in 2019. Valuation good at 17.5x vs. peers. Many of their products are essential services which is anothe tailwind.
Show full opinionHide full opinionLikes it very much. Thought bought Covidien, a medical device maker, a few years back. They're executing very well, such as their diabetes franchise which boosted their guidance recently to 5.5% growth in 2019. Valuation good at 17.5x vs. peers. Many of their products are essential services which is anothe tailwind.
PAST TOP PICK
PAST TOP PICK
September 18, 2018
(A Top Pick November 13, 2017. Up 24%). He owned this as a diversified play on the medical device market. He sold the stock when it reached $90 and used the proceeds to buy Boston Scientific instead.
(A Top Pick November 13, 2017. Up 24%). He owned this as a diversified play on the medical device market. He sold the stock when it reached $90 and used the proceeds to buy Boston Scientific instead.
Medtronic Inc(MDT-N) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 7
Neutral - Hold Signals / Votes : 1
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 8
Medtronic Inc(MDT-N) Frequently Asked Questions
What is Medtronic Inc stock symbol?
Medtronic Inc is a American stock, trading under the symbol MDT-N on the New York Stock Exchange (MDT). It is usually referred to as NYSE:MDT or MDT-N
Is Medtronic Inc a buy or a sell?
In the last year, 8 stock analysts published opinions about MDT-N. 7 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Medtronic Inc.
Is Medtronic Inc a good investment or a top pick?
Medtronic Inc was recommended as a Top Pick by Jamie Murray on 2020-11-23. Read the latest stock experts ratings for Medtronic Inc.
Why is Medtronic Inc stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Medtronic Inc worth watching?
8 stock analysts on Stockchase covered Medtronic Inc In the last year. It is a trending stock that is worth watching.
What is Medtronic Inc stock price?
On 2020-12-04, Medtronic Inc (MDT-N) stock closed at a price of $113.85.
A large medical tech company, one of the largest in that field. It is a nice industry that he likes. They deliver consistent earnings growth. It is more of an oligopoly market. It could be a core holding in a portfolio to get medical technology exposure. He holds BSX-N, however.